CBD has a long and rich history with mankind. Humans have been cultivating cannabis since almost years BCE. In , scientists and physicians began . CBD-rich cannabis has a long history of being used to treat health problems. Queen Victoria used CBD-rich cannabis for menstrual cramps in the 19th century. Hemp has been cultivated and used in China since around BC. Learn how this amazing plant has shaped history, and now potentially alter how we view.
CBD of The History
Loewe conducted the first CBD test on lab animals. That same year Dr. Further research continued in the s on primates and finally, the first CBD oil meant for therapeutic use was released by the British Pharmacopoeia.
In the next few decades, the research continued. Mechoulam made another breakthrough in CBD history when he ran a study which showed cannabidiol could be a key factor in treating epilepsy. Today, the stigma surrounding CBD is starting to disappear as people are finally beginning to see its true potential. The main factors in regards to its legality depends on a number of important factors determined by each specific state.
The one crucial factor across all states is in relation to where the CBD is derived from, marijuana or hemp. Even though CBD supplements made from industrial hemp are legal in all 50 states, there have still been some legal challenges.
Today, CBD is used to relieve symptoms of numerous conditions, from anxiety and mental illness to chronic pain. When it comes to healing, people use products such as CBD oil , CBD water and various CBD lotions to try and treat pain, inflammation, depression, anxiety, stress and other illnesses.
Some people even replace classic painkillers and other medication with CBD products, claiming that they have a better effect and treat their symptoms quicker with little to no side effects.
Nobody can know for sure what the future will bring but we can always be optimistic. Since more and more people are seeing the benefits of CBD and hemp, it looks increasingly likely that hemp will be fully legalized in the U.
Scientists are still researching CBD and conducting experiments that reveal its beneficial uses. There are many organizations that are lobbying for the total legalization of hemp and they just might succeed. The market is getting saturated with many different CBD brands. In addition, states may permit the addition of approved indications; list is subject to change. Some of the most common policy questions regarding medical cannabis now include how to regulate its recommendation and indications for use; dispensing, including quality and standardization of cultivars or strains, labeling, packaging, and role of the pharmacist or health care professional in education or administration; and registration of approved patients and providers.
The regulation of cannabis therapy is complex and unique; possession, cultivation, and distribution of this substance, regardless of purpose, remain illegal at the federal level, while states that permit medicinal cannabis use have established individual laws and restrictions on the sale of cannabis for medical purposes.
In a U. Department of Justice memorandum to all U. Cole noted that despite the enactment of state laws authorizing marijuana production and sale having a regulatory structure that is counter to the usual joint efforts of federal authorities working together with local jurisdictions, prosecution of individuals cultivating and distributing marijuana to seriously ill individuals for medicinal purpose has not been identified as a federal priority.
There are, however, other regulatory implications to consider based on the federal restriction of cannabis. Medical cannabis expenses are not reimbursable through government medical assistance programs or private health insurers. As previously described, the Schedule I listing of cannabis according to federal law and DEA regulations has led to difficulties in access for research purposes; nonpractitioner researchers can register with the DEA more easily to study substances in Schedules II—V compared with Schedule I substances.
For example, the Center for Medicinal Cannabis Research at the University of California—San Diego had access to funding, marijuana at different THC levels, and approval for a number of clinical research trials, and yet failed to recruit an adequate number of patients to conduct five major trials, which were subsequently canceled.
The limited availability of clinical research to support or refute therapeutic claims and indications for use of cannabis for medicinal purposes has frequently left both state legislative authorities and clinicians to rely on anecdotal evidence, which has not been subjected to the same rigors of peer review and scrutiny as well-conducted, randomized trials, to validate the safety and efficacy of medicinal cannabis therapy.
Furthermore, although individual single-entity pharmaceutical medications, such as dronabinol, have been isolated, evaluated, and approved for use by the FDA, a plant cannot be patented and mass produced by a corporate entity. The Schedule I designation of cannabis causes hospitals and other care settings that receive federal funding, either through Medicare reimbursement or other federal grants or programs, to pause to consider the potential for loss of these funds should the federal government intercede and take action if patients are permitted to use this therapy on campus.
Similarly, licensed practitioners registered to certify patients for state medicinal cannabis programs may have comparable concerns regarding jeopardizing their federal DEA registrations and ability to prescribe other controlled substances as well as jeopardizing Medicare reimbursements. Attorney General Eric Holder recommended that enforcement of federal marijuana laws not be a priority in states that have enacted medicinal cannabis programs and are enforcing the rules and regulations of such a program; despite this, concerns persist.
The argument for or against the use of medicinal cannabis in the acute care setting encompasses both legal and ethical considerations, with the argument against use perhaps seeming obvious on its surface. States adopting medical cannabis laws may advise patients to utilize the therapy only in their own residence and not to transport the substances unless absolutely necessary.
Canada has adopted national regulations to control and standardize dried cannabis for medical use. The argument can be made that an herb- or plant-based entity cannot be identified by pharmacy personnel as is commonly done for traditional medicines, although medicinal cannabis dispensed through state programs must be labeled in accordance with state laws.
Dispensing and storage concerns, including an evaluation of where and how this product should be stored e. Inpatient use of medicinal cannabis also carries implications for nursing and medical staff members. The therapy cannot be prescribed, and states may require physicians authorizing patient use to be registered with local programs.
Despite the complexities in the logistics of continuing medicinal cannabis in the acute care setting, proponents of palliative care and continuity of care argue that prohibiting medicinal cannabis use disrupts treatment of chronic and debilitating medical conditions.
Patients have been denied this therapy during acute care hospitalizations for reasons stated above. Legislation in Minnesota, as one example, has been amended to permit hospitals as facilities that can dispense and control cannabis use; similar legislative actions protecting nurses from criminal, civil, or disciplinary action when administering medical cannabis to qualified patients have been enacted in Connecticut and Maine.
Despite lingering controversy, use of botanical cannabis for medicinal purposes represents the revival of a plant with historical significance reemerging in present day health care.
Legislation governing use of medicinal cannabis continues to evolve rapidly, necessitating that pharmacists and other clinicians keep abreast of new or changing state regulations and institutional implications.
Ultimately, as the medicinal cannabis landscape continues to evolve, hospitals, acute care facilities, clinics, hospices, and long-term care centers need to consider the implications, address logistical concerns, and explore the feasibility of permitting patient access to this treatment. Whether national policy—particularly with a new presidential administration—will offer some clarity or further complicate regulation of this treatment remains to be seen. The authors report no commercial or financial interests in regard to this article.
National Center for Biotechnology Information , U. Journal List P T v. Author information Copyright and License information Disclaimer. This article has been cited by other articles in PMC. Open in a separate window. Access to marijuana through home cultivation, dispensaries, or some other system that is likely to be implemented;. Allows either smoking or vaporization of some kind of marijuana products, plant material, or extract.
Schedules of controlled substances. Department of Justice; Management of substance abuse: Behavioral health trends in the United States: Office of National Drug Control Policy. Answers to frequently asked questions about marijuana.
Medicinal use of marijuana—polling results. N Engl J Med. Kondrad E, Reid A. J Am Board Fam Med. Moeller KE, Woods B. Am J Pharm Educ. National Conference of State Legislatures. State medical marijuana laws. Food and Drug Administration. FDA work on medical products containing marijuana. Food and Drug Administration; Mar, A Complete Guide to Cannabis.
Park Street Press; Early medical use of cannabis. The Marihuana Tax Act of The advisability and feasibility of developing USP standards for medical cannabis. Pharmacopeial Convention; [Accessed August 5, ]. Encyclopedia of Drug Policy. State marijuana laws in map. Comparing cannabis with tobacco—again.
National Institute on Drug Abuse. Should marijuana be a medical option? MacDonald K, Pappas K. A multi-facet therapeutic target. Care and feeding of the endocannabinoid system: International Union of Basic and Clinical Pharmacology. Cannabinoid receptors and their ligands: Current status and prospects for cannabidiol preparations as new therapeutic agents. Zhornitsky S, Potvin S. Cannabidiol in humans—the quest for therapeutic targets.
Pharmaceuticals Basel ; 5: Is legalization impacting the way people use cannabis? Int J Drug Policy. Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol, and cannabinol.
Controlled cannabis vaporizer administration: Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Pharmacokinetics and pharmacodynamics of cannabinoids. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: Sativex oral mucosal spray. Marinol dronabinol capsules USP prescribing information. Adverse health effects of marijuana use.
Association between cannabis and psychosis: Keep off the grass? Cannabis, cognition, and addiction. Marijuana and lung diseases. Curr Opin Pulm Med. Cannabis use and risk of psychiatric disorders: Early cannabis use and estimated risk of later onset of depression spells: Cannabis, ischemic stroke, and transient ischemic attack: Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana: Acute and long-term effects of cannabis use: Examining the roles of cannabinoids in pain and other therapeutic indications: Adverse effects of medical cannabinoids: Lynch ME, Campbell F.
Cannabinoids for treatment of chronic noncancer pain: Br J Clin Pharmacol. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev. Gloss D, Vickrey B. American Academy of Neurology. Efficacy and safety of the therapeutic use of medical marijuana cannabis in selected neurologic disorders. Efficacy and safety of medical cannabinoids in older subjects: State-by-state medical marijuana laws.
WHAT IS CBD OIL?
CBD oil is incredibly popular today, but modern CBD history actually stretches back to the s, when scientists first isolated and began. Cannabidiol (CBD) is a phytocannabinoid discovered in It is one of some identified .. regard CBD products, including CBD oil, as a novel food in the UK, having no history of use before May , and indicating such products must . From Charlotte's Web CBD Oil to Roger Adams' work, research has proven that We delved into hemp history and found the truth: cannabidiol is everywhere.